Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
AKT3
REST API REST API
Homo sapiens
AKT3 is differentially expressed in 363 experiments: 200 organism parts: bone marrow, brain, ... (198 more);, 275 disease states: normal, control, ... (273 more);, 131 cell types 598 cell lines 39 compound treatments and 79 other conditions.
Synonyms PKBG, PRKBG, RAC-gamma
Orthologs AKT3 (2 of 2) (Danio rerio)   ENSCING00000008043 (Ciona intestinalis)   AKT3 (Bos taurus)   Akt3 (Mus musculus)   AKT3 (1 of 2) (Danio rerio)   AKT3 (Gallus gallus)   F1MA91_RAT (Rattus norvegicus)   Akt1 (Drosophila melanogaster)   SCH9 (Saccharomyces cerevisiae)   Q6PVW1_CANFA (Canis familiaris)   (Compare orthologs)
Gene Ontology Term plasma membrane, protein binding, cytoplasm, Golgi apparatus, protein tyrosine kinase activity, ATP binding, nucleus, mitochondrial genome maintenance, nucleotide binding, protein serine/threonine kinase activity, signal transduction, protein kinase activity, protein phosphorylation
InterPro Term Pkinase_C, AGC-kinase_C, Prot_kinase_cat_dom, Pleckstrin_homology, Ser/Thr_kinase_dom, Tyr_kinase_cat_dom, Ser-Thr/Tyr_kinase, Se/Thr_kinase-like_dom
UniProt Accession Q9Y243, F8VS91
Search EB-eye ENSG00000117020
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-17189, E-GEOD-803, E-GEOD-15765, E-GEOD-22541, E-GEOD-6573, ... (36 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-MEXP-1006, E-GEOD-18005, E-GEOD-2450, E-MTAB-62, ... (52 experiments)

Factor Value U/D Experiments
BT474
3
E-MTAB-37, E-MTAB-62, E-MEXP-440
HL-60
3
E-MTAB-37, E-GEOD-24147, E-GEOD-5258
MCF-7
3
E-GEOD-19639, E-GEOD-20081, E-GEOD-5823
PC3
3
E-GEOD-5258, E-MEXP-2034, E-GEOD-14464
SW480
3
E-GEOD-18005, E-MEXP-1014, E-GEOD-2509
A549
2
E-GEOD-3202, E-GEOD-6013
592 more value(s).


Cell type

studied in E-MEXP-1121, E-GEOD-21668, E-GEOD-3920, E-MEXP-750, E-GEOD-20677, ... (61 experiments)

Factor Value U/D Experiments
induced pluripotent stem cell
2
E-GEOD-18147, E-GEOD-18265
stromal cell
2
3
E-GEOD-1460, E-MEXP-2034, E-MEXP-1327, E-GEOD-10797, E-MEXP-1121 ... (5 experiments)
endothelial cell
1
2
E-GEOD-19240, E-GEOD-3920, E-GEOD-3998
fibroblast
1
2
E-GEOD-3204, E-GEOD-3920, E-GEOD-26672
epidermoid
1
E-GEOD-19397
CD4 positive T-cell
1
E-GEOD-6338
125 more value(s).


Disease state

studied in E-GEOD-3307, E-MEXP-1121, E-GEOD-1577, E-TABM-15, E-GEOD-16363, ... (78 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
3
E-MTAB-37, E-MEXP-231, E-GEOD-2514
prostate carcinoma
3
E-MEXP-2034, E-MTAB-62, E-GEOD-96
cervical carcinoma
1
3
E-MTAB-62, E-MTAB-37, E-GEOD-5823, E-MEXP-1331
adrenocortical carcinoma
2
E-GEOD-10927, E-TABM-311
benign prostatic hyperplasia
2
E-MEXP-2034, E-MEXP-1243
colon carcinoma
2
E-MTAB-37, E-MTAB-62
269 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5741, E-GEOD-1417, E-TABM-782, E-GEOD-3720, ... (26 experiments)

Factor Value U/D Experiments
none
4
8
E-GEOD-5824, E-MEXP-1958, E-MEXP-1230, E-GEOD-5099, E-GEOD-412, ... (12 experiments)
lipopolysaccharide
2
E-MEXP-1958, E-TABM-868
NaOH
1
1
E-MEXP-2590
MIG control
1
1
E-GEOD-15811
interleukin-19 (Homo sapiens)
1
E-GEOD-7216
interleukin-4 (Homo sapiens)
1
E-GEOD-5099
33 more value(s).


Age at diagnosis

studied in E-GEOD-3494

Factor Value U/D Experiments
32
2
1
E-GEOD-3494


Agent
studied in E-GEOD-19519

Biopsy tissue
studied in E-GEOD-5851

Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

cd1a
studied in E-GEOD-22601

Cell treatment
studied in E-MEXP-1192

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, ... (12 experiments)

Clinical info
studied in E-GEOD-19743, E-MEXP-1251, E-GEOD-21374, E-GEOD-4619, E-GEOD-21589, ... (13 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-MEXP-2359, E-GEOD-2666, E-GEOD-4667, ... (8 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-89, E-GEOD-1323, E-GEOD-19743, E-GEOD-22544, E-GEOD-3325, ... (12 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-21589, E-GEOD-16363

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-GEOD-8023, E-MEXP-1482, E-GEOD-7578, E-GEOD-20847, E-MTAB-108, ... (8 experiments)

Genotype
studied in E-MEXP-1437, E-TABM-1029, E-GEOD-17476, E-GEOD-22593, E-TABM-601, ... (14 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-5681, E-GEOD-20540, E-GEOD-10315, E-MEXP-1273, E-TABM-263, ... (14 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-20194, E-GEOD-16716

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-GEOD-3720, ... (35 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-2405, E-GEOD-12108, E-GEOD-12254, E-MEXP-561, ... (8 experiments)

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-MEXP-958, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-GEOD-2004, E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-26495, E-GEOD-1309, E-GEOD-21750, E-GEOD-17636, E-GEOD-4600, ... (6 experiments)

Population
studied in E-MTAB-197, E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-MEXP-1509, E-MEXP-101, E-GEOD-3697, E-MEXP-1857

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-18995

Sex
studied in E-GEOD-8052, E-GEOD-7307, E-GEOD-16363

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-MEXP-973, E-GEOD-19246, E-GEOD-19136, E-GEOD-13818, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-89, E-GEOD-4290, E-GEOD-3494, E-GEOD-22541, E-GEOD-1561, ... (6 experiments)

Tumor size
studied in E-GEOD-6532

Processing time: 0.485 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM